1. The technology to conquer glaucoma
Chris Pulling
CEO
cpulling@microoptx.com
2. BG Implant Overview
ο Novel nanotechnology implant that shunts aqueous directly to the
tear film without risk of internal infection
ο >$1MM already invested by principals; >$3.4MM total
ο Just closing $2.2MM series B
ο Funding through 10 patient US feasibility trial
ο Successful prototype development with foundational bench and
animal data
ο Proven, expert and hands-on leadership team
ο Clear and achievable regulatory AND reimbursement path
3. Glaucoma
ο Common : 105 million WW, doubling in 20 years
ο Devastating : second leading cause of blindness
in the world (cataracts)
ο Leading cause of irreversible blindness
ο polls show shorter life preferred over
blindness
ο Unmet Need : no treatment universally accepted
as safe and effective; WHO has dropped
glaucoma screening
4. The Brown Glaucoma Implant
ο Shunts directly to the tear film
ο No bleb
ο Not shunting to enclosed space within eye; scarring/plugging is not a failure mode
ο No episcleral venous pressure component => resorption, nocturnal supine IOP
increase
ο Has a filter providing precise flow control (P=RxF)
ο Filter is the only source of resistance to AH outflow
ο Engineered to achieve 8-12mmHg IOP
ο Surface biocompatibility good; hydration shell in inner lumen resists
attachments of proteins, cells, and bacteria
ο Bulk biocompatibility good. Rigidity match with sclera + surface
biointegration = no micromotion
ο Three issued patents; two provisionals filed
9. Pressure in 2-Week Flow Test
0 48 96 144 192 240 288 336
0
10
20
30
40
50
PressureDrop(mmHg)
Time (hour)
Flow rate: 2.5 ml/min (physiological)
10. Complete Bacterial Exclusion after 2-weeks
Outlet Inlet Flow
No bacteria were found
inside the device
BacterialBroth
11. Initial Animal Safety Testing
ο Easily implantable
ο Tolerated well
ο Securely scarred into place
ο No infection, with no PMNs or bacteria seen
within or around the device
ο Constant AH bathing of cornea not irritant
ο OSD, dry eye
12. MicroOptx Summary
ο Shunts AH directly to the tear film: no bleb; no EVP
component to raise nocturnal IOP
ο Hits Threshold IOP, and no hypotony
ο Inner lumen PEG: resists bacterial, protein, and cell
adherence
ο Biointegrates with sclera, so no tunnel infection risk
ο In human trials in 9-12 months